1
|
Big Data Management in Drug–Drug Interaction: A Modern Deep Learning Approach for Smart Healthcare. BIG DATA AND COGNITIVE COMPUTING 2022. [DOI: 10.3390/bdcc6010030] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
The detection and classification of drug–drug interactions (DDI) from existing data are of high importance because recent reports show that DDIs are among the major causes of hospital-acquired conditions and readmissions and are also necessary for smart healthcare. Therefore, to avoid adverse drug interactions, it is necessary to have an up-to-date knowledge of DDIs. This knowledge could be extracted by applying text-processing techniques to the medical literature published in the form of ‘Big Data’ because, whenever a drug interaction is investigated, it is typically reported and published in healthcare and clinical pharmacology journals. However, it is crucial to automate the extraction of the interactions taking place between drugs because the medical literature is being published in immense volumes, and it is impossible for healthcare professionals to read and collect all of the investigated DDI reports from these Big Data. To avoid this time-consuming procedure, the Information Extraction (IE) and Relationship Extraction (RE) techniques that have been studied in depth in Natural Language Processing (NLP) could be very promising. Since 2011, a lot of research has been reported in this particular area, and there are many approaches that have been implemented that can also be applied to biomedical texts to extract DDI-related information. A benchmark corpus is also publicly available for the advancement of DDI extraction tasks. The current state-of-the-art implementations for extracting DDIs from biomedical texts has employed Support Vector Machines (SVM) or other machine learning methods that work on manually defined features and that might be the cause of the low precision and recall that have been achieved in this domain so far. Modern deep learning techniques have also been applied for the automatic extraction of DDIs from the scientific literature and have proven to be very promising for the advancement of DDI extraction tasks. As such, it is pertinent to investigate deep learning techniques for the extraction and classification of DDIs in order for them to be used in the smart healthcare domain. We proposed a deep neural network-based method (SEV-DDI: Severity-Drug–Drug Interaction) with some further-integrated units/layers to achieve higher precision and accuracy. After successfully outperforming other methods in the DDI classification task, we moved a step further and utilized the methods in a sentiment analysis task to investigate the severity of an interaction. The ability to determine the severity of a DDI will be very helpful for clinical decision support systems in making more accurate and informed decisions, ensuring the safety of the patients.
Collapse
|
2
|
Tuya N, Wang Y, Tong L, Gao W, Yu R, Xue L. Trichosanthin enhances the antitumor effect of gemcitabine in non-small cell lung cancer via inhibition of the PI3K/AKT pathway. Exp Ther Med 2017; 14:5767-5772. [PMID: 29285119 PMCID: PMC5740788 DOI: 10.3892/etm.2017.5286] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2016] [Accepted: 07/14/2017] [Indexed: 12/30/2022] Open
Abstract
Gemcitabine (GEMZ) is the first-line therapy used against non-small cell lung cancer (NSCLC), and studies have focused on investigating the potential effects of agents combined with GEMZ to enhance the anticancer efficacy in NSCLC. Previous studies have reported that trichosanthin (TCS) has various physiological and pharmacological effects, including anti-human influenza virus enzymes, inhibition of protein synthesis and antitumor activity. The purpose of the present study was to investigate if TCS enhanced the antitumor effects of GEMZ in NSCLC. MTT assay demonstrated that TCS significantly enhanced the cytotoxic effect of GEMZ (P>0.05). Furthermore, a propidium iodide/Αnnexin V staining assay revealed that TCS exerted its pharmacological effect by increasing the apoptotic population. In addition, western blot analysis demonstrated that the combination treatment of TCS with GEMZ further decreased the expression level of phosphoinositide 3-kinase (PI3K) and AKT via regulating the expression of insulin growth factor. The results of the present study demonstrated that TCS enhanced the cytotoxic and apoptotic effects of GEMZ in A549 cells via regulating the PI3K/AKT pathway. In conclusion, these observations may provide a potential rational basis for a combination strategy for chemotherapy treatment of NSCLC.
Collapse
Affiliation(s)
- Naren Tuya
- Department of Biology, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.,Department of Radiation Oncology, General Hospital of Beijing Military Region, Beijing 100700, P.R. China.,Department of Chemotherapy Oncology, Inner Mongolia People's Hospital, Hohhot, Inner Mongolia 010020, P.R. China
| | - Yadi Wang
- Department of Biology, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.,Department of Radiation Oncology, General Hospital of Beijing Military Region, Beijing 100700, P.R. China
| | - Lanmei Tong
- Department of Chemotherapy Oncology, Inner Mongolia People's Hospital, Hohhot, Inner Mongolia 010020, P.R. China
| | - Weishi Gao
- Department of Chemotherapy Oncology, Inner Mongolia People's Hospital, Hohhot, Inner Mongolia 010020, P.R. China
| | - Rong Yu
- Department of Radiation Oncology, Inner Mongolia Cancer Hospital, Hohhot, Inner Mongolia 010020, P.R. China
| | - Liying Xue
- Department of Chemotherapy Oncology, Inner Mongolia People's Hospital, Hohhot, Inner Mongolia 010020, P.R. China
| |
Collapse
|
3
|
Xu B, Tao ZZ. Piceatannol Enhances the Antitumor Efficacy of Gemcitabine in Human A549 Non-Small Cell Lung Cancer Cells. Oncol Res 2016; 22:213-217. [PMID: 26351210 PMCID: PMC7838451 DOI: 10.3727/096504015x14386062091398] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
To enhance the anticancer efficacy of gemcitabine in the treatment of non-small cell lung cancer (NSCLC), the potential synergistic effect of piceatannol on gemcitabine cytotoxicity was investigated in the human NSCLC A459 cell line. The MTT cell viability assay showed that piceatannol significantly enhanced the cytotoxic effects of gemcitabine by lowering the gemcitabine IC50 value. Flow cytometry analysis revealed that piceatannol exerted its pharmacological effect mainly by increasing the late apoptotic population. Western blot analysis showed that gemcitabine induced the expression of the proapoptotic proteins Bad and Bak, and pretreatment with piceatannol further increased Bak expression, leading to an increased number of cells undergoing late apoptosis. The findings from this study show that piceatannol can enhance the cytotoxic effects of gemcitabine by enhancing expression of the proapoptotic protein Bak, thereby providing the rational basis for a novel combination strategy for the treatment of NSCLC.
Collapse
Affiliation(s)
- Bin Xu
- Department of Oncology, Wuhan University Renmin Hospital, Wuhan, Hubei, P.R. China
| | | |
Collapse
|
4
|
Siniscalchi A, Scaglione F, Sanzaro E, Iemolo F, Albertini G, Quirino G, Manes MT, Gratteri S, Mercuri NB, De Sarro G, Gallelli L. Effects of phenobarbital and levetiracetam on PR and QTc intervals in patients with post-stroke seizure. Clin Drug Investig 2015; 34:879-86. [PMID: 25385363 DOI: 10.1007/s40261-014-0243-9] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
BACKGROUND AND OBJECTIVES Sudden unexplained/unexpected death (SUDEP) is related to high mortality in patients with epilepsy. The prolongation of QT interval, involved in cardiac arrhythmia-related SUDEP, may be precipitated by antiepileptic drugs (AEDs). In this study, we evaluated the effects of phenobarbital and levetiracetam on PR-QTc intervals in patients with post-stroke seizures. METHODS We performed an open-label, parallel group, prospective, multicenter study between June 2009 and December 2013 in patients older than 18 years of age with a clinical diagnosis of post-stroke seizure and treated with phenobarbital or levetiracetam. In order to exclude a role of cerebral post-stroke injury on modulation of PR and QTc intervals, patients with cerebral post-stroke injury and without seizures were also enrolled as controls. RESULTS Interictal electrocardiography analysis revealed no significant difference in PR interval between patients treated with an AED (n = 49) and control patients (n = 50) (181.25 ± 12.05 vs. 182.4 ± 10.3 ms; p > 0.05). In contrast, a significantly longer QTc interval was recorded in patients treated with an AED compared with control patients (441.2 ± 56.6 vs. 396.8 ± 49.3 ms; p < 0.01). Patients treated with phenobarbital showed a significantly longer QTc interval than patients treated with levetiracetam (460.0 ± 57.2 vs. 421.5 ± 50.1 ms; p < 0.05). CONCLUSIONS The study reported that in patients with late post-stroke seizures, phenobarbital prolonged QTc interval more so than levetiracetam.
Collapse
|
5
|
Serra R, Grande R, Buffone G, Scarcello E, Tripodi F, Rende P, Gallelli L, de Franciscis S. Effects of glucocorticoids and tumor necrosis factor-alpha inhibitors on both clinical and molecular parameters in patients with Takayasu arteritis. J Pharmacol Pharmacother 2014; 5:193-6. [PMID: 25210399 PMCID: PMC4156830 DOI: 10.4103/0976-500x.136101] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2014] [Revised: 02/08/2014] [Accepted: 02/15/2014] [Indexed: 12/20/2022] Open
Abstract
Objective: To explore the effect of sequential treatment with glucocorticoid and tumor necrosis factor-alpha inhibitors in patients with Takayasu arteritis (TA). Materials and Methods: In five patients with TA, the effects of the sequential treatment with prednisone for 5-7 months and then with adalimumab (ADA) + methotrexate (MTX) or infliximab + MTX, or with ADA only, for 12 months on both clinical and laboratory findings were evaluated. Results: All treatments improved both symptoms and laboratory parameters without the development of side-effects. Conclusions: It was hypothesized that MMP-9 and neutrophil gelatinase-associated lipocalin could be markers of the response to the treatments.
Collapse
Affiliation(s)
- Raffaele Serra
- Department of Medical and Surgical Science, Interuniversity Center of Phlebolymphology, International Research and Educational Program in Clinical and Experimental Biotechnology, Catanzaro, Italy
| | - Raffaele Grande
- Department of Medical and Surgical Science, Interuniversity Center of Phlebolymphology, International Research and Educational Program in Clinical and Experimental Biotechnology, Catanzaro, Italy
| | - Gianluca Buffone
- Department of Medical and Surgical Science, Interuniversity Center of Phlebolymphology, International Research and Educational Program in Clinical and Experimental Biotechnology, Catanzaro, Italy
| | - Edoardo Scarcello
- Department of Surgery, Unit of Vascular Surgery, Annunziata Hospital of Cosenza, Cosenza, Italy
| | - Fabio Tripodi
- Department of Pharmacological, Biological and Chemical Science, University of Parma, Parma, Italy
| | - Pierandrea Rende
- Department of Health Science, University Magna Graecia of Catanzaro, Catanzaro, Italy
| | - Luca Gallelli
- Department of Health Science, University Magna Graecia of Catanzaro, Catanzaro, Italy
| | - Stefano de Franciscis
- Department of Medical and Surgical Science, Interuniversity Center of Phlebolymphology, International Research and Educational Program in Clinical and Experimental Biotechnology, Catanzaro, Italy
| |
Collapse
|
6
|
Mumoli L, Gambardella A, Labate A, Succurro E, De Sarro G, Arturi F, Gallelli L. Rosacea-like facial rash related to metformin administration in a young woman. BMC Pharmacol Toxicol 2014; 15:3. [PMID: 24507578 PMCID: PMC3923099 DOI: 10.1186/2050-6511-15-3] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2013] [Accepted: 02/04/2014] [Indexed: 11/17/2022] Open
Abstract
Background Since the skin represents a common site of adverse drug reactions, few data are reported at this time regarding the development of skin rash during the treatment with antidiabetic drugs. Case presentation We report a 29-year old woman that developed a facial skin rash during the treatment with metformin. Clinical and laboratory findings excluded the presence of systemic diseases, but several diagnosis and many drugs were administered without clinical improvement. The self-dismission of metformin induced an improvement of symptoms, while the re-challenge documented an impairments of skin rash. The Naranjo probability scale suggested a probable association between metformin and skin rash and metformin was definitively dismissed. Conclusion We report for the first time a non vasculitis facial skin manifestation related to metformin in a young woman. However, this case may emphasizes the need to consider the ADRs as a differential diagnosis in order to reduce medical errors and the related medical costs.
Collapse
Affiliation(s)
| | | | | | | | | | - Franco Arturi
- Department of Medical and Surgical Science, Division of Internal Medicine, University "Magna Graecia"- Mater Domini Hospital of Catanzaro, Catanzaro, Italy.
| | | |
Collapse
|
7
|
Staltari O, Cilurzo F, Caroleo B, Greco A, Corasaniti F, Genovesi MA, Gallelli L. Annual report on adverse events related with vaccines use in Calabria (Italy): 2012. J Pharmacol Pharmacother 2013; 4:S61-5. [PMID: 24347985 PMCID: PMC3853672 DOI: 10.4103/0976-500x.120951] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Vaccines are administered to large population of healthy individuals, particularly to millions of infants every year, through national immunization programs. Although vaccines represent a good defense against some infectious diseases, their administration may be related with the development of adverse vaccine events (AVEs); therefore their use is continually monitored to detect these side effects. In the presents work, we reported the suspected AVEs recorded in 2012 in Calabria, Italy. We performed a retrospective study on report forms of patients that developed AVEs in Calabria from January 1, 2012 to December 31, 2012. Naranjo score was used to evaluate the association between AVEs and vaccines and only suspected AVEs definable as certain, probable, or possible were included in this analysis. During the study period, we evaluated 461 records of adverse drug reactions (ADRs) and 18 (3.9%) were probably induced by vaccination. AVEs were common in females (almost 77.7%) and in children aged 0-3 years. The largest number of non-serious AVEs involved “skin and subcutaneous tissue disorders” and “general disorders and administration site conditions.” In conclusion, we documented that in Calabria the total number of AVEs is very low and it may be useful to increase the pharmacovigilance culture in order to evaluate the safety of these products in large populations.
Collapse
Affiliation(s)
- Orietta Staltari
- Centro Regionale di Informazione sul farmaco, AO Mater Domini, Catanzaro, and Department of Health Science, School of Medicine, University of Catanzaro, Italy
| | - Felisa Cilurzo
- Centro Regionale di Informazione sul farmaco, AO Mater Domini, Catanzaro, and Department of Health Science, School of Medicine, University of Catanzaro, Italy
| | - Benedetto Caroleo
- Centro Regionale di Informazione sul farmaco, AO Mater Domini, Catanzaro, and Department of Health Science, School of Medicine, University of Catanzaro, Italy
| | - Alexia Greco
- Centro Regionale di Informazione sul farmaco, AO Mater Domini, Catanzaro, and Department of Health Science, School of Medicine, University of Catanzaro, Italy
| | - Francesco Corasaniti
- Centro Regionale di Informazione sul farmaco, AO Mater Domini, Catanzaro, and Department of Health Science, School of Medicine, University of Catanzaro, Italy
| | | | - Luca Gallelli
- Centro Regionale di Informazione sul farmaco, AO Mater Domini, Catanzaro, and Department of Health Science, School of Medicine, University of Catanzaro, Italy
| |
Collapse
|
8
|
Rende P, Paletta L, Gallelli G, Raffaele G, Natale V, Brissa N, Costa C, Gratteri S, Giofrè C, Gallelli L. Retrospective evaluation of adverse drug reactions induced by antihypertensive treatment. J Pharmacol Pharmacother 2013; 4:S47-50. [PMID: 24347982 PMCID: PMC3853669 DOI: 10.4103/0976-500x.120954] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
The use of cardiovascular drugs is related to the development of adverse drug reactions (ADRs) in about 24% of the patients in the Cardiovascular Care Unit. Here, we evaluated the ADRs in patients treated with antihypertensive drugs. The study was conducted in two phases: In the first phase, we performed a retrospective study on clinical records of Clinical Divisions (i.e., Internal Medicine Operative Unit and Geriatric Operative Unit) from January 1, 2012 to December 31, 2012. Moreover from January 1, 2013 to March 30, 2013 we performed a prospective study on the outpatients attending the Emergency Department (ED) of the Pugliese-Ciaccio Hospital of Catanzaro, by conducting patient interviews after their informed consent was obtained. The association between a drug and ADR was evaluated using the Naranjo scale. We recorded 72 ADRs in the Clinical Divisions and six in the ED, and these were more frequent in women. Using the Naranjo score, we showed a probable association in 92% of these reactions and a possible association in 8%. The most vulnerable age group involved in ADRs was that of the elderly patients. In conclusion, our results indicate that antihypertensive drugs may be able to induce the development of ADRs, particularly in elderly women receiving multiple drug treatment. Therefore, it is important to motivate the healthcare providers to understand their role and responsibility in the detection, management, documentation, and reporting of ADRs, as also all the essential activities for optimizing patient safety.
Collapse
Affiliation(s)
- Pierandrea Rende
- Centro Regionale di Informazione sul farmaco, AO Mater Domini, Catanzaro, and Department of Health Science, School of Medicine, University of Catanzaro, Italy
| | - Laura Paletta
- Centro Regionale di Informazione sul farmaco, AO Mater Domini, Catanzaro, and Department of Health Science, School of Medicine, University of Catanzaro, Italy
| | | | | | | | | | - Cinzia Costa
- Centro Regionale di Informazione sul farmaco, AO Mater Domini, Catanzaro, and Department of Health Science, School of Medicine, University of Catanzaro, Italy
| | - Santo Gratteri
- Centro Regionale di Informazione sul farmaco, AO Mater Domini, Catanzaro, and Department of Health Science, School of Medicine, University of Catanzaro, Italy
| | - Chiara Giofrè
- Centro Regionale di Informazione sul farmaco, AO Mater Domini, Catanzaro, and Department of Health Science, School of Medicine, University of Catanzaro, Italy
| | - Luca Gallelli
- Centro Regionale di Informazione sul farmaco, AO Mater Domini, Catanzaro, and Department of Health Science, School of Medicine, University of Catanzaro, Italy
| |
Collapse
|
9
|
Leporini C, Rende A, Sorrentino A, Rizzica E, Russo E, Gallelli L, De Sarro G. Efficacy and safety of off-label use of fondaparinux in the management of heparin-induced thrombocytopenia with thrombosis in an elderly woman. J Clin Pharmacol 2013; 53:999-1002. [PMID: 23832870 DOI: 10.1002/jcph.124] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2013] [Accepted: 05/25/2013] [Indexed: 11/08/2022]
Affiliation(s)
- Christian Leporini
- Centro Regionale di Informazione sul Farmaco, AO Mater Domini, Catanzaro, Italy
| | | | | | | | | | | | | |
Collapse
|
10
|
De Vuono A, Scicchitano F, Palleria C, Russo E, De Sarro G, Gallelli L. Lack of efficacy during the switch from brand to generic allopurinol. J Forensic Leg Med 2013; 20:540-2. [PMID: 23756530 DOI: 10.1016/j.jflm.2013.02.007] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2012] [Revised: 01/03/2013] [Accepted: 02/05/2013] [Indexed: 01/17/2023]
|
11
|
Interactions among Low Dose of Methotrexate and Drugs Used in the Treatment of Rheumatoid Arthritis. Adv Pharmacol Sci 2013; 2013:313858. [PMID: 23737767 PMCID: PMC3667469 DOI: 10.1155/2013/313858] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2013] [Revised: 04/09/2013] [Accepted: 04/16/2013] [Indexed: 12/26/2022] Open
Abstract
Methotrexate (MTX) is a nonbiological disease-modifying antirheumatic drug that has shown both a good control of clinical disease and a good safety. Usually drug-drug interactions (DDIs) represent the most limiting factor during the clinical management of any disease, in particular when several drugs are coadministered to treat the same disease. In this paper, we report the interactions among MTX and the other drugs commonly used in the management of rheumatoid arthritis. Using Medline, PubMed, Embase, Cochrane libraries, and Reference lists, we searched for the articles published until June 30, 2012, and we reported the most common DDIs between MTX and antirheumatic drugs. In particular, clinically relevant DDIs have been described during the treatment with MTX and NSAIDs, for example, diclofenac, indomethacin, or COX-2 inhibitors, and between MTX and prednisone or immunosuppressant drugs (e.g., leflunomide and cyclosporine). Finally, an increase in the risk of infections has been recorded during the combination treatment with MTX plus antitumor necrosis factor-α agents. In conclusion, during the treatment with MTX, DDIs play an important role in both the development of ADRs and therapeutic failure.
Collapse
|
12
|
Lim SK, Shin DH, Choi MH, Kim JS. Enhanced antitumor efficacy of gemcitabine-loaded temperature-sensitive liposome by hyperthermia in tumor-bearing mice. Drug Dev Ind Pharm 2013; 40:470-6. [DOI: 10.3109/03639045.2013.768631] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
13
|
Siniscalchi A, Gallelli L, De Sarro G, Malferrari G, Santangelo E. Antiepileptic drugs for central post-stroke pain management. Pharmacol Res 2011; 65:171-5. [PMID: 21925602 DOI: 10.1016/j.phrs.2011.09.003] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/28/2011] [Revised: 08/28/2011] [Accepted: 09/05/2011] [Indexed: 12/14/2022]
Abstract
Antiepileptic drugs (AEDs) are commonly prescribed for a wide range of disorders other than epilepsy, including both neurological and psychiatric disorders. AEDs play also a role in pharmacological management of neuropathic pain. Central post-stroke pain (CPSP) is a disabling morbidity occurring in 35% of patients with stroke. The pathophysiology of CPSP is not well known but central disinhibition with increased neuronal excitability has been suggested. AEDs include many different drugs acting on pain through several mechanisms, such as reduction of neuronal hyperexcitability. To our knowledge conclusive evidence has not been published yet. The aim of this review is to delineate efficacy and safety of AEDs in CPSP.
Collapse
Affiliation(s)
- A Siniscalchi
- Department of Neuroscience, Neurology Division, Annunziata Hospital, Cosenza, Italy
| | | | | | | | | |
Collapse
|
14
|
Sugiyama E, Kaniwa N, Kim SR, Hasegawa R, Saito Y, Ueno H, Okusaka T, Ikeda M, Morizane C, Kondo S, Yamamoto N, Tamura T, Furuse J, Ishii H, Yoshida T, Saijo N, Sawada JI. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms. Clin Pharmacokinet 2010; 49:549-58. [PMID: 20608756 DOI: 10.2165/11532970-000000000-00000] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
BACKGROUND AND OBJECTIVE Gemcitabine (2',2'-difluorodeoxycytidine) is an anticancer drug, which is effective against solid tumours, including non-small-cell lung cancer and pancreatic cancer. After gemcitabine is transported into cells by equilibrative and concentrative nucleoside transporters, it is phosphorylated by deoxycytidine kinase (DCK) and further phosphorylated to its active diphosphorylated and triphosphorylated forms. Gemcitabine is rapidly metabolized by cytidine deaminase (CDA) to an inactive metabolite, 2',2'-difluorodeoxyuridine (dFdU), which is excreted into the urine. Toxicities of gemcitabine are generally mild, but unpredictable severe toxicities such as myelosuppression and interstitial pneumonia are occasionally encountered. The aim of this study was to determine the factors, including genetic polymorphisms of CDA, DCK and solute carrier family 29A1 (SLC29A1 [hENT1]), that alter the pharmacokinetics of gemcitabine in Japanese cancer patients. PATIENTS AND METHODS 250 Japanese cancer patients who received 30-minute intravenous infusions of gemcitabine at 800 or 1000 mg/m2 in the period between September 2002 and July 2004 were recruited for this study. However, four patients were excluded from the final model built in this study because they showed bimodal concentration-time curves. Two patients who experienced gemcitabine-derived life-threatening toxicities in October 2006 and January 2008 were added to this analysis. One of these patients received 30-minute intravenous infusions of gemcitabine at 454 mg/m2 instead of the usual dose (1000 mg/m2). Plasma concentrations of gemcitabine and dFdU were measured by high-performance liquid chromatography-photodiode array/mass spectrometry. In total, 1973 and 1975 plasma concentrations of gemcitabine and dFdU, respectively, were used to build population pharmacokinetic models using nonlinear mixed-effects modelling software (NONMEM version V level 1.1). RESULTS AND DISCUSSION Two-compartment models fitted well to plasma concentration-time curves for both gemcitabine and dFdU. Major contributing factors for gemcitabine clearance were genetic polymorphisms of CDA, including homozygous CDA*3 [208G>A (Ala70Thr)] (64% decrease), heterozygous *3 (17% decrease) and CDA -31delC (an approximate 7% increase per deletion), which has a strong association with CDA*2 [79A>C (Lys27Gln)], and coadministered S-1, an oral, multicomponent anti-cancer drug mixture consisting of tegafur, gimeracil and oteracil (an approximate 19% increase). The estimated contribution of homozygous CDA*3 to gemcitabine clearance provides an explanation for the life-threatening severe adverse reactions, including grade 4 neutropenia observed in three Japanese patients with homozygous CDA*3. Genetic polymorphisms of DCK and SLC29A1 (hENT1) had no significant correlation with gemcitabine pharmacokinetic parameters. Aging and increased serum creatinine levels correlated with decreased dFdU clearance. CONCLUSION A population pharmacokinetic model that included CDA genotypes as a covariate for gemcitabine and dFdU in Japanese cancer patients was successfully constructed. The model confirms the clinical importance of the CDA*3 genotype.
Collapse
Affiliation(s)
- Emiko Sugiyama
- Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Gallelli L, Colosimo M, Tolotta GA, Falcone D, Luberto L, Curto LS, Rende P, Mazzei F, Marigliano NM, De Sarro G, Cucchiara S. Prospective randomized double-blind trial of racecadotril compared with loperamide in elderly people with gastroenteritis living in nursing homes. Eur J Clin Pharmacol 2009; 66:137-44. [PMID: 19902197 DOI: 10.1007/s00228-009-0751-3] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2009] [Accepted: 10/18/2009] [Indexed: 11/24/2022]
Affiliation(s)
- Luca Gallelli
- School of Medicine and Surgery, Department of Experimental and Clinical Medicine, University Magna Graecia of Catanzaro, Mater Domini University Hospital, Catanzaro, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Bonnichon A, Vedrine L, Aletti M, Le Moulec S, Borne M, Margery J, Bauduceau O, Fayolle M, Ceccaldi B. [Favorable outcome of gemcitabine-induced acute respiratory distress syndrome]. REVUE DE PNEUMOLOGIE CLINIQUE 2007; 63:379-383. [PMID: 18166944 DOI: 10.1016/s0761-8417(07)78425-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
Gemcitabine is a new important drug used to treat solid tumors including non-small cell lung cancer, pancreatic, bladder and breast cancers. Myelosuppression is the most common adverse effect. Pulmonary toxicity is rare and usually mild and self-limiting with acute dyspnea. Severe pneumonitis and potentially fatal acute respiratory distress syndrome (ARDS) have been described in patients treated for a non-small cell lung cancer. We report a case of gemcitabine-induced ARDS in a 72-year old patient treated with gemcitabine and cisplatin for a bladder cancer without lung metastasis. Administration of high doses of corticosteroids led to a prompt symptomatic improvement.
Collapse
Affiliation(s)
- A Bonnichon
- Service des Maladies Respiratoires, Hôpital d'Instruction des Armées Percy, 101, avenue Henri-Barbusse, 92140 Clamart.
| | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Sugiyama E, Kaniwa N, Kim SR, Kikura-Hanajiri R, Hasegawa R, Maekawa K, Saito Y, Ozawa S, Sawada JI, Kamatani N, Furuse J, Ishii H, Yoshida T, Ueno H, Okusaka T, Saijo N. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol 2007; 25:32-42. [PMID: 17194903 DOI: 10.1200/jco.2006.06.7405] [Citation(s) in RCA: 152] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Gemcitabine is rapidly metabolized to its inactive metabolite, 2',2'-difluorodeoxyuridine (dFdU), by cytidine deaminase (CDA). We previously reported that a patient with homozygous 208A alleles of CDA showed severe adverse reactions with an increase in gemcitabine plasma level. This study extended the investigation of the effects of CDA genetic polymorphisms on gemcitabine pharmacokinetics and toxicities. PATIENTS AND METHODS Genotyping of CDA was performed by a direct sequencing of DNA obtained from the peripheral blood of Japanese gemcitabine-naïve cancer patients (n = 256). The patients recruited to the association study received a 30-minute intravenous infusion of gemcitabine at a dose of either 800 or 1,000 mg/m2, and eight blood samples were periodically collected (n = 250). Plasma levels of gemcitabine and dFdU were measured by high-performance liquid chromatography. Plasma CDA activities toward cytidine and gemcitabine were also measured (n = 121). RESULTS Twenty-six genetic variations, including 14 novel ones and two known nonsynonymous single nucleotide polymorphisms (SNPs), were detected. Haplotypes harboring the nonsynonymous SNPs 79A>C (Lys27Gln) and 208G>A (Ala70Thr) were designated *2 and *3, respectively. The allelic frequencies of the two SNPs were 0.207 and 0.037, respectively. Pharmacokinetic parameters of gemcitabine and plasma CDA activities significantly depended on the number of haplotype *3. Haplotype *3 was also associated with increased incidences of grade 3 or higher neutropenia in the patients who were coadministered fluorouracil, cisplatin, or carboplatin. Haplotype *2 showed no significant effect on gemcitabine pharmacokinetics. CONCLUSION Haplotype *3 harboring a nonsynonymous SNP, 208G>A (Ala70Thr), decreased clearance of gemcitabine, and increased incidences of neutropenia when patients were coadministered platinum-containing drugs or fluorouracil.
Collapse
Affiliation(s)
- Emiko Sugiyama
- Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Gallelli L, Colosimo M, Pirritano D, Ferraro M, De Fazio S, Marigliano NM, De Sarro G. Retrospective Evaluation of Adverse??Drug Reactions Induced??by??Nonsteroidal Anti-Inflammatory Drugs. Clin Drug Investig 2007; 27:115-22. [PMID: 17217316 DOI: 10.2165/00044011-200727020-00004] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
BACKGROUND AND OBJECTIVE Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most widely prescribed drugs, and their use can be complicated by the development of adverse drug reactions (ADRs). The aim of this study was to assess the frequency of NSAID-induced ADRs in hospitalised patients in the Clinical Divisions of the Catanzaro and Cosenza hospitals. METHODS We retrospectively analysed NSAID-induced ADRs after evaluating all ADRs recorded by the Clinical Divisions of the Catanzaro and Cosenza hospitals over a 10-year period, from January 1995 to December 2004. RESULTS NSAIDs were found to be responsible for 55.2% of the episodes of ADRs overall. Diclofenac and aspirin (acetylsalicylic acid) were the drugs most frequently involved in the development of ADRs, while the skin was the body system most susceptible to NSAID-induced ADRs (43%). We determined that the drug-ADR relationship was probable in 62% of the reports; withdrawal of NSAID therapy led to a resolution of the clinical features of ADRs in 86% of episodes. CONCLUSION NSAID therapy represents a common cause of ADRs in hospitalised patients. Their use should be carefully considered, especially in the presence of polydrug therapy.
Collapse
Affiliation(s)
- L Gallelli
- Department of Experimental and Clinical Medicine, Faculty of Medicine and Surgery, University Magna Graecia of Catanzaro, Mater Domini University Hospital, Catanzaro, Italy.
| | | | | | | | | | | | | |
Collapse
|
19
|
Ando T, Ichikawa J, Okamoto A, Tasaka K, Nakao A, Hamada Y. Gemcitabine inhibits viability, growth, and metastasis of osteosarcoma cell lines. J Orthop Res 2005; 23:964-9. [PMID: 16023013 DOI: 10.1016/j.orthres.2005.01.010] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 01/21/2005] [Indexed: 02/04/2023]
Abstract
Gemcitabine (dFdCyd) is an analog of cytosine arabinoside with anti-tumor activity in several human cancers. However, the efficacy of this compound in osteosarcoma has not been fully elucidated. Here we assessed the anti-tumor activity of gemcitabine using osteosarcome cell lines. In 9 human osteosarcoma cell lines (G292, HOS, MG63, NY, SaOS, HuO, HuO-3N1, HuO9, HuO9-N2), gemcitabine at the doses of >100 nM showed significant cytotoxicity. In HOS and MG63 cell lines, gemcitabine inhibited DNA synthesis as determined by IdU labeling assay and induced apoptosis as determined by DNA fragmentation assay and May-Giemsa staining. In C3H mice inoculated s.c. with a murine osteosarcoma cell line, LM8, treatment of the mice with gemcitabine showed reduced size of the primary tumor associated with increased apoptotic cells and a virtual absence of metastatic lesions in the lung. Gemcitabine thus had anti-tumor activity on osteosarcoma cell lines both in vitro and in vivo. The result would provide a cellular basis for application of gemcitabine to patients with osteosarcoma.
Collapse
Affiliation(s)
- Takashi Ando
- Department of Orthopaedic Surgery, Faculty of Medicine, University of Yamanashi, 1110, Shimokato, Tamaho, Yamanashi 409-3898, Japan.
| | | | | | | | | | | |
Collapse
|